Pfizer Inc ((PFE)), Astellas Pharma ((ALPMF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. and Astellas Pharma Inc. are conducting a study titled ‘Real-world Clinical Outcomes With Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Flatiron Health Electronic Health Records (EHR) Database.’ The study aims to understand the duration of treatment with apalutamide and enzalutamide in men with mCSPC, a common cancer in men that has spread and is controlled by lowering testosterone levels.
The study focuses on two drugs, apalutamide and enzalutamide, which are used to treat mCSPC. These drugs are androgen receptor pathway inhibitors, designed to manage prostate cancer by blocking the effects of androgens.
This observational study uses a cohort model and retrospective time perspective, analyzing real-world data from cancer clinics. It does not involve random allocation or masking, as it examines existing patient records to assess treatment duration.
The study began on July 18, 2025, with the latest update submitted on August 5, 2025. These dates indicate the study’s ongoing status and recent progress in data collection and analysis.
The study’s findings could influence Pfizer’s and Astellas Pharma’s stock performance by providing insights into the effectiveness of their prostate cancer treatments. This could impact investor sentiment positively, especially if the results show favorable outcomes compared to competitors in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.